Astellas to Terminate Offer for CV Therapeutics
16 Marzo 2009 - 12:42AM
Business Wire
Astellas Pharma Inc. (�Astellas�) today announced that it will
terminate its $16.00 per share offer for CV Therapeutics, Inc.
(Nasdaq: CVTX) and will not propose directors for the CV
Therapeutics Board of Directors or make any other proposals at CV
Therapeutics� 2009 annual meeting. Astellas also intends to
withdraw a related lawsuit in the Delaware Chancery Court against
CV Therapeutics and its directors. Astellas is a disciplined
acquirer and does not see value for Astellas stockholders in CV
Therapeutics at the price level of the sale announced on March
12.
About Astellas
Astellas Pharma Inc., with global headquarters in Tokyo and US
headquarters in Deerfield, Illinois, is a pharmaceutical company
dedicated to improving the health of people around the world
through the provision of innovative and reliable pharmaceutical
products. The organization is committed to becoming a global
pharmaceutical company by combining outstanding R&D and
marketing capabilities and continuing to grow in the world
pharmaceutical market.
Astellas was formed by the historical merger of Japan's third
and fifth largest pharmaceutical companies - Yamanouchi, founded in
1923, and Fujisawa, founded in 1894. Today, Astellas is one of the
largest pharmaceutical companies in Japan with a market
capitalization of approximately $17.7 billion as of January 26,
2009, and, for the fiscal year ended March 31, 2008, net income of
approximately $1.8 billion.
The company has approximately 14,000 employees worldwide. This
includes 7,500 in Japan, 3,300 in Europe, 2,200 in North America
and 1,000 in Asia. Some of Astellas� core products in the US are:
Lexiscan� (regadenoson) and Adenoscan� (adenosine injection),
pharmacologic stress agents indicated for radionuclide myocardial
perfusion imaging/scintigraphy (MPI/S) in patients unable to
undergo adequate exercise stress; Prograf� (tacrolimus), an
immunosuppressant indicated for the prophylaxis of organ rejection
in patients receiving organ transplants; and VESIcare� (solifenacin
succinate), indicated for the treatment of overactive bladder with
symptoms of urgency, frequency, and urge incontinence.
Astellas is publicly traded on the Tokyo Stock Exchange. For
more information about Astellas Pharma Inc., please visit
www.astellas.com. For more information about Astellas Pharma US,
Inc., please visit http://www.us.astellas.com/.
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about CV Therapeutics (MM) (NASDAQ): 0 recent articles
Más de Astellas Pharma Inc. ArtÃculos de Noticias